MBRK Middlebrook Pharmaceuticals (MM)

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) has launched a website for MOXATAG (extended-release amoxicillin) Tablets, 775 mg. MOXATAG is the first and only FDA-approved once-daily amoxicillin, and now healthcare professionals and patients have access to a comprehensive online resource for information about treating pharyngitis and tonsillitis, also known as strep throat, with MOXATAG at http://www.moxatag.com.

Visitors to the MOXATAG website can learn about the causes, symptoms and treatment of pharyngitis and tonsillitis. A video shows how MiddleBrook�s proprietary drug delivery technology, PULSYS�, prolongs the release and absorption of amoxicillin from MOXATAG to effectively treat bacterial pharyngitis and tonsillitis at a daily dose of 775 mg, which is lower than currently prescribed aminopenicillin therapies. The site also features an informative FAQ section, complete product prescribing information and information for pharmacists.

MiddleBrook President and CEO John Thievon said, �MOXATAG is a unique product with no AB-rated generic, and MOXATAG has valuable benefits for patients and prescribers. The MOXATAG website showcases MOXATAG�s attributes and illustrates the compliance-enhancing benefits of once-daily dosing.�

�A review of the latest available data indicates that approximately 3,000 prescriptions have been filled for MOXATAG through April 24, with steady week-over-week growth,� Thievon continued. �This is in line with our expectations, given launch timing and the seasonality of pharyngitis and tonsillitis, and we anticipate more than half of the total 2009 MOXATAG prescription volume to be generated in the fourth quarter. The MOXATAG.com website will support the efforts of our national field sales force and serve as a valuable adjunct to our nationwide print media campaign directed at healthcare professionals as we work to increase awareness for MOXATAG, the first and only FDA-approved once-daily amoxicillin.�

MiddleBrook Pharmaceuticals Reports Inducement Grants Under NASDAQ Marketplace Rule 4350

MiddleBrook Pharmaceuticals also announced today that on April 30, 2009, it granted options to purchase a total 21,000 shares of MiddleBrook's common stock to five (5) new employees as a material inducement for them to join MiddleBrook. The options were granted pursuant to NASDAQ Marketplace Rule 4350(i)(1)(A)(iv) and under MiddleBrook's New Hire Stock Incentive Plan, which was approved by MiddleBrook's Board of Directors on Sept. 26, 2008. The options have a per share exercise price equal to the closing price of MiddleBrook's common stock on the NASDAQ Global Market on the business day immediately preceding the grant date, a ten-year term and vesting over four years, with 25 percent of the options vesting one year from the grant date and 1/48th of the options vesting monthly thereafter. The options have a grant date of April 30, 2009.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. We have developed a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. We are currently developing a portfolio of anti-infective PULSYS products. Our near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which we believe will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG � the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

About MOXATAG:

MOXATAG (amoxicillin extended-release) Tablets, 775mg, is a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components of MOXATAG are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. For more information about MOXATAG, please visit www.moxatag.com.

Forward-Looking Statements:

This announcement contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, that involve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "potential, " "estimate, " "will," "may," �predict,� "should, " "could, " "would" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations," and elsewhere in our Annual Report on Form 10-K for the year ended Dec. 31, 2008, and in similar disclosures made by us from time to time in our other filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission. KEFLEX, MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., M1 (stylized), MOX-10, MOXAKIT, MOXATAG1 (stylized), MOXATAG, MOXATEN, MOX-PAK and PULSYS are our trademarks and have been registered in the U.S. Patent and trademark office or are the subject of pending U.S. trademarks applications. Each of the other trademarks, tradenames, or service marks appearing in this document belongs to the respective holder. As used herein, except as otherwise indicated by the context, references to �we,� �us,� �our,� �MiddleBrook,� or the �Company,� refer to MiddleBrook Pharmaceuticals, Inc., and its subsidiaries.

Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Apr 2024 a Mag 2024

Grafico Azioni Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Storico
Da Mag 2023 a Mag 2024